Letters
Free Access
ASH 2009 meeting report—Top 10 clinically oriented abstracts in chronic lymphocytic leukemia†
Susan O'Brien,
Corresponding Author
Susan O'Brien
Department of Leukemia, UT MD Anderson Cancer Center, Houston, Texas
UT MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd. Unit 428, Houston, Texas 77030Search for more papers by this authorSusan O'Brien,
Corresponding Author
Susan O'Brien
Department of Leukemia, UT MD Anderson Cancer Center, Houston, Texas
UT MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd. Unit 428, Houston, Texas 77030Search for more papers by this authorFirst published: 08 January 2010
†
Conflict of interest: Nothing to report.
References
- 1RaiKR,PetersonBL,AppelbaumFR, et al.Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.N Engl J Med2000; 343: 1750–1757.
- 2LeoniLM,BaileyB,ReifertJ, et al.Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.Clin Cancer Res2008; 14: 309–317.
- 3KnaufWU,LissichkovT,AldaoudA, et al.Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.J Clin Oncol2009; 27: 4378–4384.
- 4ChesonBD,RummelMJ.Bendamustine: Rebirth of an old drug.J Clin Oncol2009; 27: 1492–1501.
- 5RummelMJ,ChowKU,HoelzerD, et al: In vitro studies with bendamustine: Enhanced activity in combination with rituximab.Semin Oncol2002; 29: 12–14.
- 6TeelingJL,FrenchRR,CraggMS, et al.Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.Blood2004; 104: 1793–1800.
- 7TeelingJL,MackusWJM,WiegmanLJJM, et al.The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.J Immunol2006; 177: 362–371.
- 8Chanan-KhanA,MillerKC,MusialL, et al.Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.J Clin Oncol2006; 24: 5343–5349.
- 9FerrajoliA,LeeB-N,SchletteEJ, et al.Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.Blood2008; 111: 5291–5297.
- 10KeatingMJ,O'BrienS,AlbitarM, et al.Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.J Clin Oncol2005; 23: 4079–4088.
- 11TamCS,O'BrienS,WierdaW, et al.Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.Blood2008; 112: 975–980.
- 12CertoM,Del Gaizo MooreV,NishinoM, et al.Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.Cancer Cell2006; 9: 351–365.
- 13ChenL,WillisSN,WeiA, et al.Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.Mol Cell2005; 17: 393–403.
- 14WillisSN,FletcherJI,KaufmannT, et al.Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs not bax or bak.Science2007; 315: 856–859.
- 15RobakT.GA-101, a third-generation, humanized and glycol-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.Curr Opin Investig Drugs2009; 10: 588–596.
- 16KnobelochKP,WrightMD,OchsenbeinAF, et al.Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions.Mol Cell Biol2000; 20: 5363–5369.
- 17ZhaoX,LapalombellaR,JoshiT, et al.Targeting CD27-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.Blood2007; 110: 2569–2577.
